CG Invites Co., Ltd.

A083790

KR7083790006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 21/05/2024 BST			5-day change	1st Jan Change
2,620 ^KRW	-1.69%		-9.19%	-5.59%

04-18	Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	CI
03-27	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI

CrystalGenomics, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.

February 15, 2022 at 08:17 am

CrystalGenomics, Inc. (KOSDAQ:A083790) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with Korea Investment & Securities. The program will expire on May 16, 2022.

Latest news about CG Invites Co., Ltd.

Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	04-17	CI
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	03-26	CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	03-17	CI
CG Invites Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period	01-24	CI
An unknown buyer cancelled the acquisition of 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc.	12-13	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	11/10/23	CI
Crystal Bio Sciences Co., Ltd announced that it has received KRW 10 billion in funding from CrystalGenomics Invites Co., LTD.	11/10/23	CI
CrystalGenomics Invites Co., LTD.(KOSDAQ:A083790) dropped from S&P Global BMI Index	24/08/23	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23	CI
CrystalGenomics, Inc. announced that it has received KRW 62.427998592 billion in funding from New Lake Invites Investment Co., Ltd., Osung Advanced Materials Co., Ltd.	01/06/23	CI
CrystalGenomics Invites Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
An unknown buyer agreed to acquire approximately 2.40% stake in CrystalGenomics, Inc. from Kumho HT, Inc for KRW 28 billion.	29/03/23	CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.	21/11/22	CI
CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
CrystalGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
CrystalGenomics, Inc. announced that it has received KRW 5.7075 billion in funding from Kumho HT, Inc	07/08/22	CI
CrystalGenomics, Inc. announced that it expects to receive KRW 5.7075 billion in funding from Kumho HT, Inc	28/07/22	CI
CrystalGenomics, Inc. announced that it has received KRW 21.9999994 billion in funding	23/06/22	CI
CrystalGenomics, Inc. announced that it expects to receive KRW 21.9999994 billion in funding	12/06/22	CI
CrystalGenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.	16/05/22	CI
Tranche Update on CrystalGenomics, Inc.'s Equity Buyback Plan announced on February 15, 2022.	16/05/22	CI
CrystalGenomics, Inc.'s Equity Buyback announced on February 15, 2022, has expired with 688,603 shares, representing 1.01% for KRW 4,503.53 million.	15/05/22	CI

Chart CG Invites Co., Ltd.

Duration

Period

More charts

Company Profile

CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CG INVITES CO., LTD.	-5.59%	147M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+34.06%	595B
JOHNSON & JOHNSON	-2.07%	369B
MERCK & CO., INC.	+20.25%	332B
ABBVIE INC.	+2.99%	282B
ASTRAZENECA PLC	+16.62%	244B
NOVARTIS AG	+9.89%	208B
ROCHE HOLDING AG	-4.38%	205B
AMGEN INC.	+7.43%	166B

Other Pharmaceuticals

CG Invites Co., Ltd.

Equities

A083790

KR7083790006

Pharmaceuticals

CrystalGenomics, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.

Latest news about CG Invites Co., Ltd.

Chart CG Invites Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals